Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMP-001 and SBRT in early stage triple negative breast cancer
NCT04807192Phase 2Active, not recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2025
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vidutolimod in triple-negative breast cancer (TNBC), sponsored by Lausanne University Hospital. Started Apr 2021; status: active, not recruiting.
02
Drugs
vidutolimod
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04807192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04807192.